Order Article Reprints

Scognamiglio G, Capone M, Sabbatino F, Di Mauro A, Cantile M, Cerrone M, Madonna G, Grimaldi AM, Mallardo D, Palla M, et al. The Ratio of GrzB⁺ − FoxP3⁺ over CD3⁺ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. Cancers. 2021; 13(10):2325. https://doi.org/10.3390/cancers13102325

Scognamiglio, Giosuè, Mariaelena Capone, Francesco Sabbatino, Annabella Di Mauro, Monica Cantile, Margherita Cerrone, Gabriele Madonna, Antonio Maria Grimaldi, Domenico Mallardo, Marco Palla, and et al. 2021. "The Ratio of GrzB⁺ − FoxP3⁺ over CD3⁺ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma" Cancers 13, no. 10: 2325. https://doi.org/10.3390/cancers13102325

Scognamiglio, G., Capone, M., Sabbatino, F., Di Mauro, A., Cantile, M., Cerrone, M., Madonna, G., Grimaldi, A. M., Mallardo, D., Palla, M., Sarno, S., Anniciello, A. M., Di Bonito, M., Ascierto, P. A., & Botti, G. (2021). The Ratio of GrzB⁺ − FoxP3⁺ over CD3⁺ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. Cancers, 13(10), 2325. https://doi.org/10.3390/cancers13102325